GET THE APP

Elevated tumor marker CA125: Interpretations in renal disease
..

Journal of Nephrology & Therapeutics

ISSN: 2161-0959

Open Access

Elevated tumor marker CA125: Interpretations in renal disease


4th International Conference on Nephrology & Therapeutics

September 14-16, 2015 Baltimore, USA

Sohini Sengupta Neogi and L M Srivastava

Sir Gangaram Hospital, India

Scientific Tracks Abstracts: J Nephrol Ther

Abstract :

Tumor markers like CA125 are routinely used for the purpose of screening and diagnosis of several malignant conditions. Elevated levels of several tumour markers can be frequently detected in patients with impaired kidney function because of disturbed renal elimination or presence of neoplasia, given the higher risk of developing malignancies in these patients. The possibility of false positive results notably reduces the diagnostic value of those markers that are mainly eliminated by renal excretion. Our institute has a large base of nephrology patients undergoing dialysis and transplants and hence, our interest lies in this area. In our hospital, the biological reference interval (BRI) in use for CA125 is less than 35 IU/mL. The serum CA-125 level is within normal limits in majority of haemodialysis and stable CAPD patients. In peritoneal dialysis, CA 125 is elevated after peritonitis and after catheter replacement. The serum CA-125 level should be interpreted with caution in the CAPD patients as it may be a non-specific marker of peritoneal irritation. CA 125 serum level is elevated in male patients of chronic kidney disease but is not influenced by kidney transplant. The BRI for other tumour markers like fPSA, CA15.3 and CA19.9 markers in our laboratory is <0.25 ng/mL, 0-31 U/mL and 0-35 U/ mL respectively. These markers also show an increase in patients of haemodialysis. We thus conclude that elevated level of tumour markers need to be evaluated judiciously in patients of chronic renal disease particularly women in the reproductive age group to prevent them from being subjected to unnecessary exploratory interventions.

Biography :

Sohini Sengupta Neogi has completed her MD and DNB in Biochemistry from India. She is the first Post-doctoral Fellow in Laboratory Medicine from the National Board of Examinations, India. She is currently working as an Associate Consultant and Assistant Professor in the Department of Biochemistry, Sir Gangaram Hospital & Gangaram Institute of Post-graduate Medical Education & Research, India. She has several national and international publications and has presented papers in numerous conferences of repute. She has won several awards and in 2013, she has received the Best Paper Award for her oral presentation in the National Conference of Clinical Biochemists of India.

Email: drsohini9@gmail.com

Google Scholar citation report
Citations: 784

Journal of Nephrology & Therapeutics received 784 citations as per Google Scholar report

Journal of Nephrology & Therapeutics peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward